- Tufts Health Plan, with more than 1M members across Massachusetts and Rhode Island, will cover Exact Sciences' (EXAS +1%) Cologuard colorectal cancer screening test effective March 15.
- The FDA approved the test in August 2014, which the company offers as a service from its in-house laboratory. It generated $1.5M in revenues last year.
Health plan in Northeast U.S. to cover Exact's Cologuard
Recommended For You
About EXAS Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
EXAS | - | - |
Exact Sciences Corporation |